<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330823</url>
  </required_header>
  <id_info>
    <org_study_id>CARPAN-01</org_study_id>
    <nct_id>NCT01330823</nct_id>
  </id_info>
  <brief_title>L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)</brief_title>
  <acronym>CARPAN</acronym>
  <official_title>L-Carnitine in the Palliative Treatment of Advanced Pancreatic Cancer (CARPAN): a Prospective, Randomised, Placebo Controlled, Double Blinded, Multicentre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigated the role of L-Carnitine supplementation on proinflammatory immune
      response, malnutrition, cancer cachexia and cancer related fatigue in advanced and inoperable
      pancreatic cancer, UICC Stage IV .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer has the lowest 5-year survival rate of any cancer and ranks as the fourth
      leading cause of cancer death world wide. Several metabolic changes are present in the whole
      body in case of cancer so the investigators conducted a placebo controlled, double blinded,
      randomized, prospective and multicentre study to investigate, whether L-Carnitine
      supplementation may have an impact on malnutrition, cancer cachexia and cancer related
      fatigue in advanced pancreatic cancer.

      Study drug: L-Carnitine 4g per day (vers) Placebo Study design: A multi-centre, double blind,
      and placebo-controlled, randomised, parallel group study

      Patient population: Patients with advanced pancreatic carcinoma Number of patients: Total of
      90 patients in two equal groups number of centres: 4 (Greifswald, Magdeburg,
      Berlin,Heidelberg,all Germany) Duration of dosing: 12 weeks
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    after interims analysis standard errors for inflammatory and nutritional markers varied widely,
    that the power calculation required unattainable goals
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>12 weeks</time_frame>
    <description>Influence of L-Carnitine on proinflammatory cytokine TNF-alpha</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>nutritional status</measure>
    <time_frame>12 weeks</time_frame>
    <description>Bioelectrical impedance analysis (BIA) was performed,BCM / ECM index, phase angle, body fat was measured. Increase of body weight and body mass index and and also weight loss were investigated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quality of life was determined using the European EORTC QLQ-C30 form, along with an additional disease specific pancreatic cancer module PAN26 and also Brief Fatique Inventory (BFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>1 year</time_frame>
    <description>Survival time in days was calculated from time of diagnosis until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>1 year</time_frame>
    <description>time of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>L-Carnitine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L-Carnitine 4 g daily for Intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (tartaric acid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Carnitine</intervention_name>
    <description>L-Carnitine, 4g/day, orally (Juice)</description>
    <arm_group_label>L-Carnitine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tartaric acid same dose like L-Carnitine as placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  advanced pancreatic cancer (UICC Stage IV)

          -  Karnofsky Index larger than 60

          -  compliance

          -  consent to participate to the study

        Exclusion Criteria:

          -  Child-Pugh classification of liver failure greater than Child B,

          -  a known second malignant tumor

          -  oral or parenteral supplementation with omega-3-fatty acids

          -  treatment with thalidomide or Infliximab

          -  mental or physical disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus M. Lerch, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medicine Greifswald</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medicine Greifswald,Department of Medicine A</name>
      <address>
        <city>Greifswald</city>
        <zip>17489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.pancreas.de</url>
  </link>
  <link>
    <url>http://www.medizin.uni-greifswald.de/</url>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <last_update_submitted>April 6, 2011</last_update_submitted>
  <last_update_submitted_qc>April 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Markus M Lerch, Professor of Medicine</name_title>
    <organization>Department of Medicine A</organization>
  </responsible_party>
  <keyword>pancreatic carcinoma</keyword>
  <keyword>L-Carnitine</keyword>
  <keyword>quality of life</keyword>
  <keyword>survival</keyword>
  <keyword>malnutrition</keyword>
  <keyword>cancer cachexia</keyword>
  <keyword>fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

